(Q55470770)

12 July 2018

title

Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. (English)

1 reference

12 July 2018

Angela Panoskaltsis-Mortari

1 reference

5

object named as

Angela Panoskaltsis-Mortari

1 reference

12 July 2018

2

Daniel A Vallera

1 reference

12 July 2018

author name string

Edward Rustamzadeh

1

1 reference

12 July 2018

Deborah A Todhunter

3

1 reference

12 July 2018

Walter C Low

4

1 reference

12 July 2018

Walter A Hall

6

1 reference

12 July 2018

publication date

1 May 2006

1 reference

12 July 2018

Journal of Neuro-Oncology

published in

1 reference

12 July 2018

volume

77

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

page(s)

257-266

1 reference

12 July 2018

https://scigraph.springernature.com/pub.10.1007/s11060-005-9051-7

exact match

0 references

cites work

Epidemiology of brain tumors: the national survey of intracranial neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS11060-005-9051-7

Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-005-9051-7

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-005-9051-7

Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-005-9051-7

Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats

21 January 2018

1 reference

12 December 2020

Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

1 reference

12 December 2020

Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

1 reference

12 December 2020

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms

1 reference

12 December 2020

Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism

1 reference

12 December 2020

Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment

1 reference

12 December 2020

Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers

1 reference

12 December 2020

Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy

1 reference

12 December 2020

Roles of urokinase type plasminogen activator in a brain stab wound.

1 reference

12 December 2020

Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain

1 reference

12 December 2020

Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas

1 reference

12 December 2020

Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth

1 reference

12 December 2020

Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy

1 reference

12 December 2020

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

1 reference

12 December 2020

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

1 reference

12 December 2020

Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor.

1 reference

12 December 2020

Interleukin-13 receptor as a unique target for anti-glioblastoma therapy

1 reference

12 December 2020

Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice

1 reference

12 December 2020

In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.

1 reference

12 December 2020

Purification of p-nitrobenzyl C-functionalized diethylenetriamine pentaacetic acids for clinical applications using anion-exchange chromatography

1 reference

12 December 2020

Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.

1 reference

12 December 2020

Interleukin-13 and interleukin-4 act as interleukin-6 inducers in human microglial cells

1 reference

12 December 2020

Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.

1 reference

12 December 2020

Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.

1 reference

12 December 2020

Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro

1 reference

12 December 2020

National survey of patterns of care for brain-tumor patients

1 reference

12 December 2020

Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts.

1 reference

12 December 2020

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

1 reference

12 December 2020

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

1 reference

12 December 2020

Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.

1 reference

12 December 2020

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

12 December 2020

Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma

1 reference

12 December 2020

Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme.

1 reference

12 December 2020

The morbidity and mortality of brain tumors. A perspective on recent advances in therapy

1 reference

12 December 2020

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

1 reference

12 December 2020

Backbone-substituted DTPA ligands for 90Y radioimmunotherapy.

1 reference

12 December 2020

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

1 reference

12 December 2020

Radioimmunotherapy of cancer: clinical studies and limiting factors

1 reference

12 December 2020

A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model

1 reference

12 December 2020

Immunotoxin therapy for CNS tumor

1 reference

12 December 2020

Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions

1 reference

12 December 2020

Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium

1 reference

12 December 2020

Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents

1 reference

12 December 2020

In Vitro and In Vivo Variation in Transferrin Receptor Expression on a Human Medulloblastoma Cell Line

1 reference

12 December 2020

10.1007/S11060-005-9051-7

Identifiers

DOI

1 reference

12 July 2018

Dimensions Publication ID

1011101953

0 references

1 reference

12 July 2018